Telomir Pharmaceuticals (NASDAQ:TELO) Stock Price Down 5% - Here's Why

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO - Get Free Report)'s stock price dropped 5% during mid-day trading on Tuesday . The company traded as low as $2.03 and last traded at $2.10. Approximately 1,477,980 shares traded hands during trading, an increase of 69% from the average daily volume of 874,546 shares. The stock had previously closed at $2.21.

Telomir Pharmaceuticals Trading Down 4.4%

The company has a market cap of $65.17 million, a PE ratio of -5.21 and a beta of -0.90. The business has a fifty day moving average of $1.78 and a 200-day moving average of $3.04.

Telomir Pharmaceuticals (NASDAQ:TELO - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.10) by $0.03. As a group, research analysts predict that Telomir Pharmaceuticals, Inc. will post -0.4 EPS for the current year.

Institutional Trading of Telomir Pharmaceuticals

Large investors have recently bought and sold shares of the company. Bank of New York Mellon Corp boosted its position in shares of Telomir Pharmaceuticals by 40.8% in the 4th quarter. Bank of New York Mellon Corp now owns 72,295 shares of the company's stock worth $298,000 after purchasing an additional 20,931 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Telomir Pharmaceuticals by 327.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 46,406 shares of the company's stock worth $191,000 after purchasing an additional 35,556 shares in the last quarter. Virtu Financial LLC bought a new stake in shares of Telomir Pharmaceuticals in the 4th quarter worth approximately $62,000. Corebridge Financial Inc. boosted its position in shares of Telomir Pharmaceuticals by 273.8% in the 4th quarter. Corebridge Financial Inc. now owns 9,613 shares of the company's stock worth $40,000 after purchasing an additional 7,041 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its position in shares of Telomir Pharmaceuticals by 1,096.4% in the 4th quarter. JPMorgan Chase & Co. now owns 41,444 shares of the company's stock worth $171,000 after purchasing an additional 37,980 shares in the last quarter.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.